GlobeNewswire

Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)

Del

Interim data expected in the second half of 2019

NEW YORK and CLEVELAND, May 14, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company has completed dosing cohort 1 and treated the first patient in cohort 2 in an ongoing Phase 1/2 clinical trial evaluating ABO-101, its novel one-time gene therapy for Sanfilippo syndrome type B (MPS IIIB). The Company expects to report interim data from the trial in the second half of 2019.

“We believe that ABO-101 can help address the underlying lysosomal enzyme deficiency that ultimately results in progressive cell damage and neurodevelopmental and physical decline in children with MPS IIIB,” said João Siffert, M.D., Chief Executive Officer. “The product safety profile to date and clear evidence of biological activity provide support for advancing this clinical trial to the second cohort. This multicenter study is made possible by our close collaborations with expert academic investigators and the participants who enrolled to date. We look forward to presenting interim data in the second half of this year.”

The Phase 1/2 trial is a two-year, open-label, dose-escalation, global clinical trial in patients diagnosed with MPS IIIB who are older than six months of age and have a minimum cognitive Development Quotient of 60 or above. The study is expected to include up to nine patients and is designed to evaluate two doses of ABO-101 with cohort 1 receiving 2 X 1013 vg/kg and cohort 2 receiving 5 X 1013 vg/kg. ABO-101 is delivered using NAV® AAV9 technology via a one-time intravenous infusion. The primary endpoint of the study is to assess neurodevelopment and safety, with multiple secondary and exploratory endpoints including neurocognitive and behavior evaluations, quality of life, enzyme activity in cerebrospinal fluid (CSF) and plasma, biomarkers in CSF, plasma and urine, and brain and liver volume.

Abeona is enrolling eligible patients with MPS IIIB at sites in the U.S. and Spain and expects to activate additional sites globally this year to accelerate enrollment. Additional information about the study is available at AbeonaTrials.com and ClinicalTrials.gov (NCT03315182).

About Sanfilippo syndrome type B (MPS IIIB)
Sanfilippo syndrome type B (MPS IIIB) is a rare and fatal lysosomal storage disease with no approved therapy that primarily affects the central nervous system and is characterized by rapid neurodevelopmental and physical decline. Children with MPS IIIB present with progressive language and cognitive decline and behavioral abnormalities. Other symptoms include sleep problems and frequent ear infections. Additionally, distinctive signs such as facial features with thick eyebrows or a unibrow, full lips and excessive body hair for one’s age and liver/spleen enlargement are also present. The underlying cause of MPS IIIB is a deficiency in the NAGLU enzyme responsible for breaking down glycosaminoglycans, which accumulate throughout the body resulting in rapid decline associated with the disorder.

About ABO-101
ABO-101 is a novel gene therapy in Phase 1/2 development for Sanfilippo syndrome type B (MPS IIIB), a rare lysosomal storage disease with no approved therapy that primarily affects the central nervous system (CNS). ABO-101 is dosed in a one-time intravenous infusion using the NAV® AAV9 vector to deliver a functional copy of the NAGLU gene to cells of the CNS and peripheral tissues. The therapy is designed to address the underlying NAGLU enzyme deficiency responsible for abnormal accumulation of glycosaminoglycans in the brain and throughout the body that results in progressive cell damage and neurodevelopmental and physical decline. In the U.S., Abeona holds Fast Track and Rare Pediatric Disease designations for ABO-101 and Orphan Drug designation in both the U.S. and EU.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. The Company’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, as well as ABO-102 and ABO-101, novel NAV® AAV9-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively. The Company’s portfolio of AAV9-based gene therapies also features ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Its preclinical assets include ABO-401, which uses the novel AIM™ AAV vector platform to address all mutations of cystic fibrosis. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates and is the only company with Regenerative Medicine Advanced Therapy designation for two candidates (EB-101 and ABO-102). For more information, visit www.abeonatherapeutics.com.

Forward Looking Statement
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties.  These statements include statements regarding our pipeline including the potential for ABO-101 in the treatment of Sanfilippo syndrome type B, including the results of clinical studies, the ability to present interim data, the ability to continue to enroll patients in clinical studies, the ability to obtain regulatory marketing approvals, and the company’s goals and objectives.  We have attempted to identify forward looking statements by such terminology as “may,” will,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” and similar expressions.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to: continued interest in our rare disease portfolio, our ability to initiate and enroll patients in clinical trials, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks as may be detailed from time to time in the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q and other reports filed by the Company with the Securities and Exchange Commission.  The Company undertakes no obligation to revise the forward-looking statements or update them to reflect events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Investor Contact:
Sofia Warner
Senior Director, Investor Relations
Abeona Therapeutics
+1 (646) 813-4710
swarner@abeonatherapeutics.com

Media Contact:
Scott Santiamo
Director, Corporate Communications
Abeona Therapeutics
+1 (718) 344-5843
ssantiamo@abeonatherapeutics.com

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Test Release - 25-05-2019 - 21108925.5.2019 15:39:00 CESTPressemelding

Test Sub Headline - 2067088 Chicago, May 25, 2019 (GLOBE NEWSWIRE) -- American HealthCare Lending, the leading non-recourse patient financing platform serving health systems, physician groups, surgical centers, and other healthcare providers throughout the country, today announced that it will showcase its patient financing platform at the Healthcare Financial Management Association's ANI 2014 Conference in Las Vegas June 22-25. Hosted by the nation's leading membership organization for healthcare financial management executives and leaders, HFMA's 2014 National Institute is a place for top executives and key decision makers to explore solutions to the most pressing issues facing the industry. American HealthCare Lending's patient financing solution addresses one of these key issues, the dramatic rise in out-of-pocket patient responsibility, by delivering financing options designed to fulfill the company's mission to Make Healthcare Affordable™. Attachment sample

Biome Grow Inc. to Announce First Quarter Fiscal 2019 Financial Results.24.5.2019 19:08:00 CESTPressemelding

TORONTO, May 24, 2019 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE:BIO, OTCQB: BIOIF, 6OTA:GR) will release its financial results for the first quarter ended March 31, 2019 before market open on May 29, 2019. Following the release of its first quarter 2019 financial results, Biome will host a conference call and audio webcast with Khurram Malik, CEO at 8:30am Eastern Time May 29, 2019. Webcast information A live audio webcast will be available at https://event.on24.com/wcc/r/2015980/CEAD1B37BDD7710D021A38D2B79B5C45 Calling Information Toll Free Dial-In Number: 1 (866) 211 3199 International Dial-In Number (647) 689 6601 Conference ID 8693906 About Biome Biome wholly owns five subsidiaries, including: The Back Home Medical Cannabis Corporation, a company incorporated under the laws of the Province of Newfoundland and Labrador and in the late stages of applying for a license under the Cannabis Act; Great Lakes Cannabis, a company incorporated under the laws of the

Jason Lamb of Gates Foundation Named New Chair of CGAP’s Executive Committee24.5.2019 17:04:00 CESTPressemelding

CGAP CEO calls for renewed focus on retail credit to support growth and jobs for the poor Beirut, Lebanon, May 24, 2019 (GLOBE NEWSWIRE) -- Jason Lamb from the Bill & Melinda Gates Foundation, was elected chair of the Executive Committee for The Consultative Group to Assist the Poor (CGAP) at its annual meeting on Wednesday. Lamb will succeed Carolina Trivelli, senior researcher at the Instituto de Estudios Peruanos and Peru’s former Minister of Development and Social Inclusion. Under Trivelli’s leadership CGAP adopted its new five-year strategy and theory of change that places empowering the poor through financial services to capture opportunities and build resilience at the heart of CGAP’s work. At the Gates Foundation, Lamb is Deputy Director, Financial Services for the Poor (FSP) and manages focus country implementation in Bangladesh, Pakistan, Indonesia, Nigeria, Tanzania, Kenya and Uganda. He has served on CGAP’s Executive Committee, which functions like a board of directors prov

Gainsight Unveils the Customer Cloud, the Future of Customer Success Technology23.5.2019 19:30:00 CESTPressemelding

New Products Announced at Pulse 2019 to Drive Customer Success Across the Enterprise SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- Today, Gainsight® launched the Customer Cloud —a first-of-its-kind solution for subscription businesses looking to adopt a customer-centric philosophy that enables them to retain customers while also driving company growth post-sale. According to the 2018 Subscription Economy Index report, subscription companies are growing five times faster than S&P and retail sales. The Gainsight Customer Cloud caters to these businesses by combining the company’s Customer Success and Product Experience products with three new product innovations to offer a powerful set of solutions for businesses to optimize their subscription strategies through technology. “With the maturity of cloud technology and the subscription economy, customer expectations have drastically changed. Companies are struggling to leverage existing tools to satisfy the increasing demands of their cus

Lowered Return Expectations Among Several Trends Pointing to a Shift in Private Markets Due Diligence says New eVestment Survey23.5.2019 15:30:00 CESTPressemelding

ATLANTA, May 23, 2019 (GLOBE NEWSWIRE) -- Private markets funds have continued to rake in new commitments from institutional investors eager to diversify their portfolios and capture the returns private markets investments can offer. However, investors are now tempering their private markets return expectations. Coupled with other industry trends, this will have implications for private markets fundraising and due diligence according to a new eVestment report, produced in association with parent company Nasdaq. The 2019 eVestment Private Markets Due Diligence Survey of institutional investors, consultants and private markets fund managers finds that 52% of investors expect returns in the space to decline in the future (page 16). Only 12% of investors expected private equity returns to increase, with the balance – 36% – expecting returns to stay about the same. Forty-seven percent of investors surveyed expect to see lower returns in venture capital vs. just 16% of investors who expect r

Collibra Announces 2019 Excellence Awards Winners23.5.2019 15:00:00 CESTPressemelding

American Express, Deloitte, and Lloyds Banking Group recognized as leaders in harnessing data to drive digital transformation NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Collibra, the leader in enterprise data governance and catalog software, today announced the winners of the 2019 Collibra Excellence Awards. Presented at the annual Data Citizens conference in New York, the awards honor teams and individuals driving innovative data strategy by collaborating with Collibra. “In today’s market, organizations that are able to maximize data have the power to transform entire industries,” said Felix Van de Maele, co-founder and CEO of Collibra. “We’re proud to honor the recipients of the Collibra Excellence Awards, a cutting-edge group at the forefront of data-driven innovation.” The 2019 Collibra Excellence Award Winners: American Express — Distinguished Data Program of the Year American Express was recognized for its data governance transformation, which began as a compliance initiative and